Krista Fogarty - Lipocine Principal Controller
| LPCN Stock | USD 4.45 0.03 0.68% |
Insider
Krista Fogarty is Principal Controller of Lipocine
| Age | 56 |
| Address | 675 Arapeen Drive, Salt Lake City, UT, United States, 84108 |
| Phone | 801 994 7383 |
| Web | https://www.lipocine.com |
Latest Insider Transactions
Krista Fogarty Latest Insider Activity
Tracking and analyzing the buying and selling activities of Krista Fogarty against Lipocine stock is an integral part of due diligence when investing in Lipocine. Krista Fogarty insider activity provides valuable insight into whether Lipocine is net buyers or sellers over its current business cycle. Note, Lipocine insiders must abide by specific rules, including filing SEC forms every time they buy or sell Lipocine'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Krista Fogarty over six months ago Acquisition by Krista Fogarty of 991 shares of Lipocine subject to Rule 16b-3 |
Lipocine Management Efficiency
The company has return on total asset (ROA) of (0.2267) % which means that it has lost $0.2267 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3412) %, meaning that it created substantial loss on money invested by shareholders. Lipocine's management efficiency ratios could be used to measure how well Lipocine manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to grow to -0.68. In addition to that, Return On Capital Employed is likely to drop to -0.92. At this time, Lipocine's Total Assets are very stable compared to the past year. As of the 28th of November 2024, Other Assets is likely to grow to about 4 M, while Net Tangible Assets are likely to drop about 27 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Karen Harrigan | Ardelyx | N/A | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 52 | |
| Victor MD | Kodiak Sciences | 51 | |
| Scott MBA | Mustang Bio | N/A | |
| Qiyong Liu | Transcode Therapeutics | 60 | |
| MPA MD | Unicycive Therapeutics | 51 | |
| Anna Moore | Transcode Therapeutics | 62 | |
| Eliot CPA | Mustang Bio | 66 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Robyn Hunter | Mustang Bio | 62 | |
| Susan Rodriguez | Ardelyx | 60 | |
| CPA MST | Ardelyx | 50 | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 52 | |
| Jonathan Pachter | Verastem | 66 | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| Marc Cantillon | Reviva Pharmaceuticals Holdings | 66 | |
| Laxminarayan Bhat | Reviva Pharmaceuticals Holdings | 59 | |
| Daniel Calkins | Verastem | 36 | |
| John CPA | Unicycive Therapeutics | 62 | |
| Dan Pavicich | Ardelyx | N/A | |
| Laxminarayan Bhat | Reviva Pharmaceuticals Holdings | 59 | |
Management Performance
| Return On Equity | -0.34 | ||||
| Return On Asset | -0.23 |
Lipocine Leadership Team
Elected by the shareholders, the Lipocine's board of directors comprises two types of representatives: Lipocine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lipocine. The board's role is to monitor Lipocine's management team and ensure that shareholders' interests are well served. Lipocine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lipocine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Co Sec | ||
| Logan Morse, Marketing Sales | ||
| Nachiappan Chidambaram, Senior Development | ||
| M MD, Chief Director | ||
| Mahesh Patel, Co-Founder, Chairman, CEO and Pres | ||
| Krista Fogarty, Principal Controller | ||
| MD D, Chief Director |
Lipocine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lipocine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.34 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (1.77) % | ||||
| Operating Margin | (36.76) % | ||||
| Current Valuation | 3.81 M | ||||
| Shares Outstanding | 5.35 M | ||||
| Shares Owned By Insiders | 2.91 % | ||||
| Shares Owned By Institutions | 9.95 % | ||||
| Number Of Shares Shorted | 60.13 K | ||||
| Price To Earning | 15.80 X |
Pair Trading with Lipocine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipocine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipocine will appreciate offsetting losses from the drop in the long position's value.Moving against Lipocine Stock
| 0.74 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.65 | INKT | Mink Therapeutics | PairCorr |
| 0.63 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.62 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.6 | RGNX | Regenxbio | PairCorr |
The ability to find closely correlated positions to Lipocine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipocine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipocine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipocine to buy it.
The correlation of Lipocine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipocine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipocine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipocine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.75) | Revenue Per Share 0.903 | Quarterly Revenue Growth 137.519 | Return On Assets (0.23) | Return On Equity (0.34) |
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.